{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:16:20Z","timestamp":1791260180445,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"N\u00eemes University Hospital","award":["LOCAL\/2016\/CR-01"],"award-info":[{"award-number":["LOCAL\/2016\/CR-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40262-021-01062-6","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T20:02:34Z","timestamp":1640030554000},"page":"673-686","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Caspofungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-Abdominal Infections: A Prospective Cohort Study"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8338-5385","authenticated-orcid":false,"given":"Nicolas","family":"Garbez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litaty C.","family":"Mbatchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2392-9854","authenticated-orcid":false,"given":"Steven C.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8788-179X","authenticated-orcid":false,"given":"Laurent","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5965-9876","authenticated-orcid":false,"given":"Jeffrey","family":"Lipman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-435X","authenticated-orcid":false,"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7774-2497","authenticated-orcid":false,"given":"Jean-Yves","family":"Lefrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-0034","authenticated-orcid":false,"given":"Claire","family":"Roger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,21]]},"reference":[{"key":"1062_CR1","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1086\/520980","volume":"45","author":"PG Pappas","year":"2007","unstructured":"Pappas PG, Rotstein CMF, Betts RF, Nucci M, Talwar D, Waele JJD, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45:883\u201393.","journal-title":"Clin Infect Dis"},{"key":"1062_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1086\/649554","volume":"50","author":"JS Solomkin","year":"2010","unstructured":"Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJC, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the surgical infection society and the infectious diseases society of America. Clin Infect Dis. 2010;50:133\u201364.","journal-title":"Clin Infect Dis"},{"key":"1062_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1086\/504810","volume":"43","author":"KW Garey","year":"2006","unstructured":"Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25\u201331.","journal-title":"Clin Infect Dis"},{"key":"1062_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00134-014-3310-z","volume":"40","author":"M Bassetti","year":"2014","unstructured":"Bassetti M, Righi E, Ansaldi F, Merelli M, Cecilia T, De Pascale G, et al. A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med. 2014;40:839\u201345.","journal-title":"Intensive Care Med"},{"key":"1062_CR5","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1007\/s00134-012-2695-9","volume":"38","author":"A Tabah","year":"2012","unstructured":"Tabah A, Koulenti D, Laupland K, Misset B, Valles J, Bruzzi de Carvalho F, et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med. 2012;38:1930\u201345.","journal-title":"Intensive Care Med"},{"key":"1062_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13054-016-1229-1","volume":"20","author":"J-A Paiva","year":"2016","unstructured":"Paiva J-A, Pereira JM, Tabah A, Mikstacki A, de Carvalho FB, Koulenti D, et al. Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study. Crit Care. 2016;20:53.","journal-title":"Crit Care"},{"key":"1062_CR7","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/cid\/cis305","volume":"54","author":"M Kollef","year":"2012","unstructured":"Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012;54:1739\u201346.","journal-title":"Clin Infect Dis"},{"key":"1062_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/MCC.0b013e328028fd92","volume":"13","author":"SI Blot","year":"2007","unstructured":"Blot SI, Vandewoude KH, De Waele JJ. Candida peritonitis. Curr Opin Crit Care. 2007;13:195\u20139.","journal-title":"Curr Opin Crit Care"},{"key":"1062_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/jac\/dkr511","volume":"67","author":"SA Grim","year":"2012","unstructured":"Grim SA, Berger K, Teng C, Gupta S, Layden JE, Janda WM, et al. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. J Antimicrob Chemother. 2012;67:707\u201314.","journal-title":"J Antimicrob Chemother"},{"key":"1062_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","volume":"45","author":"R Bellmann","year":"2017","unstructured":"Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017;45:737\u201379.","journal-title":"Infection"},{"key":"1062_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2011.07.013","volume":"39","author":"M Sinnollareddy","year":"2012","unstructured":"Sinnollareddy M, Peake SL, Roberts MS, Lipman J, Roberts JA. Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review. Int J Antimicrob Agents. 2012;39:1\u201310.","journal-title":"Int J Antimicrob Agents"},{"key":"1062_CR12","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","volume":"37","author":"JA Roberts","year":"2009","unstructured":"Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37:840\u201351.","journal-title":"Crit Care Med"},{"key":"1062_CR13","doi-asserted-by":"publisher","first-page":"e01009-17","DOI":"10.1128\/AAC.01009-17","volume":"61","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Prideaux B, Nagasaki Y, Lee MH, Chen P-Y, Blanc L, et al. Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model. Antimicrob Agents Chemother. 2017;61:e01009-17.","journal-title":"Antimicrob Agents Chemother."},{"key":"1062_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13054-015-0758-3","volume":"19","author":"MG Sinnollareddy","year":"2015","unstructured":"Sinnollareddy MG, Roberts JA, Lipman J, Akova M, Bassetti M, De Waele JJ, et al. Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. Crit Care. 2015;19:33.","journal-title":"Crit Care"},{"key":"1062_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.accpm.2018.10.006","volume":"37","author":"J-A Jamal","year":"2018","unstructured":"Jamal J-A, Roger C, Roberts JA. Understanding the impact of pathophysiological alterations during critical illness on drug pharmacokinetics. Anaesth Crit Care Pain Med. 2018;37:515\u20137.","journal-title":"Anaesth Crit Care Pain Med."},{"key":"1062_CR16","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1093\/jac\/dku313","volume":"69","author":"EW Muilwijk","year":"2014","unstructured":"Muilwijk EW, Schouten JA, van Leeuwen HJ, van Zanten ARH, de Lange DW, Colbers A, et al. Pharmacokinetics of caspofungin in ICU patients. J Antimicrob Chemother. 2014;69:3294\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"1062_CR17","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40262-016-0495-z","volume":"56","author":"C Roger","year":"2017","unstructured":"Roger C, Wallis SC, Muller L, Saissi G, Lipman J, Br\u00fcggemann RJ, et al. Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration. Clin Pharmacokinet. 2017;56:1057\u201368.","journal-title":"Clin Pharmacokinet"},{"key":"1062_CR18","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1128\/JCM.00566-08","volume":"46","author":"MA Pfaller","year":"2008","unstructured":"Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, Rex JH, Alexander BD, Andes D, et al. Correlation of MIC with outcome for candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol. 2008;46:2620\u20139.","journal-title":"J Clin Microbiol"},{"key":"1062_CR19","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1086\/599039","volume":"48","author":"DL Horn","year":"2009","unstructured":"Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48:1695\u2013703.","journal-title":"Clin Infect Dis"},{"key":"1062_CR20","doi-asserted-by":"publisher","first-page":"e0127534","DOI":"10.1371\/journal.pone.0127534","volume":"10","author":"M Bassetti","year":"2015","unstructured":"Bassetti M, Merelli M, Ansaldi F, de Florentiis D, Sartor A, Scarparo C, et al. Clinical and therapeutic aspects of candidemia: a five year single centre study. PLoS ONE. 2015;10:e0127534.","journal-title":"PLoS ONE"},{"key":"1062_CR21","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/j.1469-0691.2010.03360.x","volume":"17","author":"P Montravers","year":"2011","unstructured":"Montravers P, Mira J-P, Gangneux J-P, Leroy O, Lortholary O. A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect. 2011;17:1061\u20137.","journal-title":"Clin Microbiol Infect"},{"key":"1062_CR22","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1128\/AAC.01584-09","volume":"54","author":"D Andes","year":"2010","unstructured":"Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against candida species. Antimicrob Agents Chemother. 2010;54:2497\u2013506.","journal-title":"Antimicrob Agents Chemother"},{"key":"1062_CR23","doi-asserted-by":"publisher","first-page":"7601","DOI":"10.1128\/AAC.04134-14","volume":"58","author":"RK Shields","year":"2014","unstructured":"Shields RK, Nguyen MH, Press EG, Clancy CJ. Abdominal candidiasis is a hidden reservoir of echinocandin resistance. Antimicrob Agents Chemother. 2014;58:7601\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"1062_CR24","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1097\/CCM.0b013e318241e553","volume":"40","author":"DM Roberts","year":"2012","unstructured":"Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P, Cole L, et al. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med. 2012;40:1523\u20138.","journal-title":"Crit Care Med"},{"issue":"2","key":"1062_CR25","first-page":"e01582","volume":"61","author":"KCM van der Elst","year":"2017","unstructured":"van der Elst KCM, Veringa A, Zijlstra Jan G, Beishuizen A, Klont R, Brummelhuis-Visser P, et al. Low caspofungin exposure in patients in the Intensive Care Unit. Antimicrob Agents Chemother. 2017;61(2):e01582-e1616.","journal-title":"Antimicrob Agents Chemother"},{"key":"1062_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ijid.2020.09.019","volume":"101","author":"F Gioia","year":"2020","unstructured":"Gioia F, Gomez-Lopez A, Alvarez ME, Gomez-Garc\u00eda de la Pedrosa E, Mart\u00edn-Davila P, Cuenca-Estrella M, et al. Pharmacokinetics of echinocandins in suspected candida peritonitis: a potential risk for resistance. Int J Infect Dis. 2020;101:24\u20138.","journal-title":"Int J Infect Dis"},{"key":"1062_CR27","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.accpm.2020.10.012","volume":"39","author":"E Toulouse","year":"2020","unstructured":"Toulouse E, Lafont B, Granier S, Mcgurk G, Bazin J-E. French legal approach to patient consent in clinical research. Anaesth Crit Care Pain Med. 2020;39:883\u20135.","journal-title":"Anaesth Crit Care Pain Med."},{"key":"1062_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.accpm.2015.03.005","volume":"34","author":"P Montravers","year":"2015","unstructured":"Montravers P, Dupont H, Leone M, Constantin J-M, Mertes P-M, Laterre P-F, et al. Guidelines for management of intra-abdominal infections. Anaesth Crit Care Pain Med. 2015;34:117\u201330.","journal-title":"Anaesth Crit Care Pain Med."},{"key":"1062_CR29","unstructured":"US FDA. Guidance for Industry: Bioanalytical Method Validation. 2018; Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM)."},{"key":"1062_CR30","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","volume":"270","author":"JR Le Gall","year":"1993","unstructured":"Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European\/North American multicenter study. JAMA. 1993;270:2957\u201363.","journal-title":"JAMA"},{"key":"1062_CR31","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1097\/00003246-199811000-00016","volume":"26","author":"JL Vincent","year":"1998","unstructured":"Vincent JL, de Mendon\u00e7a A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction\/failure in intensive care units: results of a multicenter, prospective study. Working group on \u201csepsis-related problems\u201d of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26:1793\u2013800.","journal-title":"Crit Care Med"},{"key":"1062_CR32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","volume":"34","author":"MN Neely","year":"2012","unstructured":"Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012;34:467\u201376.","journal-title":"Ther Drug Monit"},{"key":"1062_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10928-013-9302-8","volume":"40","author":"T Tatarinova","year":"2013","unstructured":"Tatarinova T, Neely M, Bartroff J, van Guilder M, Yamada W, Bayard D, et al. Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian. J Pharmacokinet Pharmacodyn. 2013;40:189\u201399.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1062_CR34","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.ejps.2017.05.056","volume":"109","author":"NHG Holford","year":"2017","unstructured":"Holford NHG, Anderson BJ. Allometric size: the scientific theory and extension to normal fat mass. Eur J Pharm Sci. 2017;109:S59-64.","journal-title":"Eur J Pharm Sci"},{"key":"1062_CR35","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1093\/jac\/dkw150","volume":"71","author":"P Colin","year":"2016","unstructured":"Colin P, Eleveld DJ, Jonckheere S, Van Bocxlaer J, De Waele J, Vermeulen A. What about confidence intervals? A word of caution when interpreting PTA simulations. J Antimicrob Chemother. 2016;71:2502\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"1062_CR36","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1128\/JCM.00308-13","volume":"51","author":"MA Pfaller","year":"2013","unstructured":"Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol. 2013;51:2571\u201381.","journal-title":"J Clin Microbiol"},{"key":"1062_CR37","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ijantimicag.2017.03.028","volume":"50","author":"MA Pfaller","year":"2017","unstructured":"Pfaller MA, Messer SA, Rhomberg PR, Castanheira M. CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program. Int J Antimicrob Agents. 2017;50:352\u20138.","journal-title":"Int J Antimicrob Agents"},{"key":"1062_CR38","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.cmi.2019.04.027","volume":"25","author":"M Sals\u00e9","year":"2019","unstructured":"Sals\u00e9 M, Gangneux J-P, Cassaing S, Delhaes L, Fekkar A, Dupont D, et al. Multicentre study to determine the Etest epidemiological cut-off values of antifungal drugs in Candida spp. and Aspergillus fumigatus species complex. Clin Microbiol Infect. 2019;25:1546\u201352.","journal-title":"Clin Microbiol Infect"},{"key":"1062_CR39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/1120009X.2020.1737783","volume":"32","author":"C Adembri","year":"2020","unstructured":"Adembri C, Villa G, Rosi E, Tofani L, Fallani S, De Gaudio AR, et al. Caspofungin PK in critically ill patients after the first and fourth doses: suggestions for therapeutic drug monitoring? J Chemother. 2020;32:124\u201331.","journal-title":"J Chemother"},{"key":"1062_CR40","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1128\/AAC.48.3.815-823.2004","volume":"48","author":"JA Stone","year":"2004","unstructured":"Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother. 2004;48:815\u201323.","journal-title":"Antimicrob Agents Chemother"},{"key":"1062_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1128\/AAC.02466-18","volume":"63","author":"S Kurland","year":"2019","unstructured":"Kurland S, Furebring M, L\u00f6wdin E, Eliasson E, Nielsen EI, Sj\u00f6lin J. Pharmacokinetics of caspofungin in critically ill patients in relation to liver dysfunction: differential impact of plasma albumin and bilirubin levels. Antimicrob Agents Chemother. 2019;63:11.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"1062_CR42","doi-asserted-by":"publisher","first-page":"e01545","DOI":"10.1128\/AAC.01545-20","volume":"64","author":"S Bailly","year":"2020","unstructured":"Bailly S, Gautier-Veyret E, L\u00ea MP, Bouadma L, Andremont O, Neuville M, et al. Impact of loading dose of caspofungin in PK\/PD target attainment for severe candidiasis infections in ICU patients\u2014the CASPOLOAD study. Antimicrob Agents Chemother. 2020;64(12):e01545-e1620.","journal-title":"Antimicrob Agents Chemother"},{"key":"1062_CR43","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1093\/jac\/dkv173","volume":"70","author":"S Grau","year":"2015","unstructured":"Grau S, Luque S, Campillo N, Sams\u00f3 E, Rodr\u00edguez U, Garc\u00eda-Bernedo CA, et al. Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. J Antimicrob Chemother. 2015;70:2854\u201361.","journal-title":"J Antimicrob Chemother"},{"key":"1062_CR44","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/jac\/dkm125","volume":"60","author":"TH Nguyen","year":"2007","unstructured":"Nguyen TH, Hoppe-Tichy T, Geiss HK, Rastall AC, Swoboda S, Schmidt J, et al. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother. 2007;60:100\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"1062_CR45","doi-asserted-by":"publisher","first-page":"e00905","DOI":"10.1128\/AAC.00905-20","volume":"64","author":"A-G M\u00e4rtson","year":"2020","unstructured":"M\u00e4rtson A-G, van der Elst KCM, Veringa A, Zijlstra JG, Beishuizen A, van der Werf TS, et al. Caspofungin weight-based dosing supported by a population pharmacokinetic model in critically ill patients. Antimicrob Agents Chemother. 2020;64:e00905-e920.","journal-title":"Antimicrob Agents Chemother"},{"key":"1062_CR46","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303\u201332.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1062_CR47","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ijantimicag.2016.01.009","volume":"47","author":"AS Alobaid","year":"2016","unstructured":"Alobaid AS, Hites M, Lipman J, Taccone FS, Roberts JA. Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: a structured review. Int J Antimicrob Agents. 2016;47:259\u201368.","journal-title":"Int J Antimicrob Agents"},{"key":"1062_CR48","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1086\/598933","volume":"48","author":"RF Betts","year":"2009","unstructured":"Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ, et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis. 2009;48:1676\u201384.","journal-title":"Clin Infect Dis"},{"key":"1062_CR49","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.1128\/AAC.05134-11","volume":"55","author":"OA Cornely","year":"2011","unstructured":"Cornely OA, Vehreschild JJ, Vehreschild MJGT, W\u00fcrthwein G, Arenz D, Schwartz S, et al. Phase II dose escalation study of caspofungin for invasive aspergillosis. Antimicrob Agents Chemother. 2011;55:5798\u2013803.","journal-title":"Antimicrob Agents Chemother"},{"key":"1062_CR50","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1128\/AAC.01912-12","volume":"57","author":"G W\u00fcrthwein","year":"2013","unstructured":"W\u00fcrthwein G, Cornely OA, Trame MN, Vehreschild JJ, Vehreschild MJGT, Farowski F, et al. Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis. Antimicrob Agents Chemother. 2013;57:1664\u201371.","journal-title":"Antimicrob Agents Chemother"},{"key":"1062_CR51","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/myc.12661","volume":"60","author":"M Sasso","year":"2017","unstructured":"Sasso M, Roger C, Sasso M, Poujol H, Barbar S, Lefrant J-Y, et al. Changes in the distribution of colonising and infecting Candida spp. isolates, antifungal drug consumption and susceptibility in a French intensive care unit: a 10-year study. Mycoses. 2017;60:770\u201380.","journal-title":"Mycoses"},{"key":"1062_CR52","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1128\/AAC.01430-10","volume":"55","author":"D Andes","year":"2011","unstructured":"Andes D, Ambrose PG, Hammel JP, Van Wart SA, Iyer V, Reynolds DK, et al. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. Antimicrob Agents Chemother. 2011;55:2113\u201321.","journal-title":"Antimicrob Agents Chemother"},{"key":"1062_CR53","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4161\/viru.26187","volume":"5","author":"J Delaloye","year":"2014","unstructured":"Delaloye J, Calandra T. Invasive candidiasis as a cause of sepsis in the critically ill patient. Virulence. 2014;5:161\u20139.","journal-title":"Virulence."},{"key":"1062_CR54","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1080\/1120009X.2017.1289308","volume":"29","author":"C Tascini","year":"2017","unstructured":"Tascini C, Sozio E, Di Paolo A, Tintori G, Leonildi A, Bertolino G, et al. Fungicidal activity and PK\/PD of caspofungin as tools to guide antifungal therapy in a fluconazole-resistant C. parapsilosis candidemia. J Chemother. 2017;29:376\u20139.","journal-title":"J Chemother"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01062-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-021-01062-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01062-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T23:57:26Z","timestamp":1652313446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-021-01062-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1062"],"URL":"https:\/\/doi.org\/10.1007\/s40262-021-01062-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,21]]},"assertion":[{"value":"27 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by academic\u00a0funding\u00a0from the Nimes University Hospital (LOCAL\/2016\/CR-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jeffrey Lipman received honoraria from MSD and Pfizer and also received institution support from MSD. Claire Roger received consultancy fees from MSD, Pfizer, and Fresenius Medical Care. Nicolas Garbez, Litaty C. Mbatchi, Steven C. Wallis, Laurent Muller, Jason A. Roberts, and Jean-Yves Lefrant have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"Ethics approval was obtained from the local ethics committee of N\u00eemes (Comit\u00e9 de Protection des Personnes Sud-M\u00e9diterran\u00e9e III 2012.02.05).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from either the patient or their designated substitute decision maker.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Pmetrics software package for R (Los Angeles, CA, USA) [\n                      \n                      ,\n                      \n                      ].","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availabitity"}},{"value":"CR, J-YL, and LM conceived and designed the study. CR collected data and SCW performed drug assay. NG, CR, J-YL, and JAR analysed data. NG carried out the pharmacokinetic analysis. NG, CR and LM drafted the manuscript. All authors read and approved the final manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"All patients provided consent for publication of their pooled, anonymized data.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets analysed during the current study are available from the corresponding author on reasonable request.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}}]}}